Autologous stem cell transplantation as post-remission therapy in adult acute myelogenous leukemia: Does platelet contamination of peripheral blood mobilized stem cell grafts influence the risk of leukemia relapse?

Journal of Hematotherapy and Stem Cell Research

Volumn 9, Issue 4, 2000, Pages 433-443

  Bruserud, O ^a   Foss, B ^a   Abrahamsen, J F ^a   Gjertsen, B T ^a   Ernst, P ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACID HYDROLASE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; BETA THROMBOGLOBULIN; CALCIUM; CATALASE; CYTARABINE; EPIDERMAL GROWTH FACTOR; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; PLATELET DERIVED GROWTH FACTOR; SEROTONIN; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; APOPTOSIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BIOLOGICAL THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CELL SURVIVAL; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE COUNT;

ADULT; BLOOD PLATELETS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033835808     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581600419099     Document Type: Review

References (101)

1. Acute myeloid leukemia
2. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukemia in first remission: A prospective controlled study
3. Randomised comparison of addition of autologous transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: Results of MRC AML 10 trial
4. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia
5. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia
6. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
7. Optimalization of peripheral blood stem cell mobilization
8. Peripheral blood stem cell mobilization for high-dose chemotherapy
9. Granulocyte-colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission
10. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia allows faster engraftment and equivalent disease-free survival compared with bone marrow
11. Peripheral blood stem cells in acute myeloid leukemia: Biology and clinical aspects
12. Composition of peripheral blod progenitor cell components collected from healthy donors
13. Collection of two peripheral blood stem cell concentrates from heathy donors
14. Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products
15. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products
16. Saturation of 1-β-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy
17. Intensive postremission chemotherapy in adults with acute myeloid leukemia
18. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
19. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison
20. In vitro culture of acute myelogenous leukemia blasts: A comparison of four different culture media
21. Application of myeloid growth factors in the treatment of acute myeloid leukemia
22. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in acute myelogenous leukemia; a review of present and possible future approaches for GM-CSF therapy
23. Autologous peripheral blood progenitor cell transplantation mobilized with high-dose cytarabine in acute myeloid leukemia in first complete remission
24. Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocyte-colony stimulating factor
25. Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone
26. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission
27. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome
28. Factors which affect the CFU-GM content of the peripheral blood haematopoietic progenitor cell harvests in patients with acute myeloid leukemia
29. Increased numbers of long-term initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor
30. Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance
31. Roles of stem cell factor in the in vitro growth of blast clonogenic cells from patients with acute myeloblastic leukemia
32. Effect of mast cell growth factor on clonogenic blast cell growth in acute myelogenous leukemia
33. Serum levels of thrombopoietin and stem cell factor in acute leukemia patients with chemotherapy-induced cytopenia and complicating infections
34. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma
35. High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkins lymphoma
36. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients
37. Gene-marking to trace origin of relapse after autologous bone marrow transplantation
38. Negative selection of autologous peripheral blood stem cells
39. Evaluation of leukemic cell contamination in peripheral blood stem cell harvests by reverse transcriptase polymerase chain reaction
40. Autologous peripheral blood stem cell transplantation in acute myeloblastic leukemia and myelodysplastic syndrome patients; evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods
41. Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia
42. Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia
43. Reconstitution of hematopoietic system with autologous marrow taken during relapse of acute myeloblastic leukemia and grown in long-term culture
44. Short-term liquid marrow cultures are supported by a mixture of haematopoietic cytokines but do not purge for acute myeloid or lymphoid leukemic marrow cells
45. Effects of normal platelets on proliferation and constitutive cytokine secretion by human acute myelogenous leukemia blasts
46. Effects of acute myelogenous leukemia blasts on platelet release of soluble P-selectin and platelet-derived growth factor
47. Flow cytometric analysis of platelet membrane antigens during and after continuous-flow plateletpheresis
48. Alteration of platelet-associated membrane glycoproteins during extracorporeal apheresis of peripheral blood progenitor cells
49. Changes in platelet membrane glycoproteins and platelet leukocyte interactions during hemodialysis
50. Detection of plasmapheresis-induced platelet activation using monoclonal antibodies
51. Detection and significance of alpha-granule membrane protein gp 140 expression on platelets collected by apheresis
52. Total body irradiation and acute graft versus host disease: The role of gastrointestinal damage and inflammatory cytokines
53. Role of tumor necrosis factor alpha in acute graft versus host disease and complications following allogeneic bone marrow transplantation
54. Positive selection of autologous peripheral blood stem cells
55. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation
56. Platelets and megakaryocytes
57. Platelet-derived growth factors
58. +-channel activity in growth factor mediated extra cellular signal-regulated kinase activation in human myeloblastic leukemia ML-1 cells
59. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
60. Effects of transforming growth factor beta 1 on growth and apoptosis of human acute myelogenous leukemia cells
61. Enhancement of transforming growth factor beta 1 (TGF-beta 1) on the proliferation of leukemic blast progenitors stimulated with IL3
62. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: Possible implications for future therapeutic stategies
63. The effect of antitubule agents on signal transduction pathways of apoptosis: A review
64. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: Possible correlation with sensitivity to chemotherapy
65. P53 mutations are associated with resistance to chemotherapy and short survival in hematological malignancies
66. Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bcl-2 dependent and independent pathways
67. Cytoprotective effects of hematopoietic growth factors on primary human acute myelogenous leukemias are not mediated through changes in bcl-2, bax, or p21WAFI/C1P1
68. Elevated expression of the apoptotic regulator MCL-1 at the time of leukemia relapse
69. Bcl-2 expression in normal human bone marrow precursors and in acute myelogenous leukemia
70. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C
71. Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: Significance for response to chemotherapy
72. Bcl-X(L) is heterogeneously expressed by acute myeloblastic leukemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression
73. Expression of the antiapoptotic MCL-1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C
74. Caspase 2 and 3 protein levels as predictors of survival in acute myelogenous leukemia
75. Phosphorylation signaling in apoptosis
76. Extracellular ATP as a trigger for apoptosis or programmed cell death
77. Effects of extracellular ATP and adenosine on different thymocyte subsets: Possible role of ATP-gated channels and G-protein-coupled purinergic receptor
78. The P2X1 receptor, an adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leukocytes
79. Mechanism of extracellular ATP- and adenosine-induced apoptosis of cultured pulmonary artery endothelial cells
80. Extracellular ATP and adenosine cause apoptosis of pulmonary artery endothelial cells
81. Extracellular ATP and ADP activate transcription factor NF-kappa B and induce endothelial cell apoptosis
82. Characterization of the cytotoxic effect of extra-cellular ATP in J774 mouse macrophages
83. Serotonin-induced calcium signalling via 5-HT1A receptors in human leukemia (K562) cells
84. The 5-HT1A receptor agonist BAY x 3702 prevents staurosporine-induced apoptosis
85. Serotonin and apoptosis
86. Alterations of extracellular calcium elicit selective modes of cell death and protease activation in SH-SY5Y human neuroblastoma cells
87. Elevated extracellular calcium can prevent apoptosis via the calcium-sensing receptor
88. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
89. VEGF deprivation-induced apoptosis is a component of programmed capillary regression
90. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling
91. Vascular endothelial growth factor inhibits death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor
92. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation
93. Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents
94. Platelet-derived growth factor induces apoptosis in growth-arrested murine fibroblasts
95. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines
96. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death
97. The role of PDGF-dependent suppression of apoptosis in differentiating 3T3-L1 preadipocytes
98. Evidence for a role of NF-κB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor β fusion protein
99. Platelet-derived growth factor-BB induces apoptosis in cultured vascular smooth muscle cells derived from human saphenous vein
100. CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia
101. Autocrine production of extracellular catalase prevents apoptosis of human CEM T cell line in serum-free medium